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MANUSCRIPT 
Abstract 
Objectives 
European guidelines state left ventricular (LV) end-diastolic wall thickness (EDWT) 
≥15mm suggests hypertrophic cardiomyopathy (HCM), but distinguishing from 
hypertensive heart disease (HHD) is challenging. We identify cardiac magnetic 
resonance (CMR) predictors of HHD over HCM when EDWT ≥15mm. 
 
Methods 
2481 consecutive clinical CMRs between 2014-15 were reviewed. 464 segments 
from 29 HCM subjects with EDWT ≥15mm but without other cardiac abnormality, 
hypertension or renal impairment were analyzed. 432 segments from 27 HHD 
subjects with EDWT ≥15mm but without concomitant cardiac pathology were 
analyzed. Magnitude and location of maximal EDWT, presence of late gadolinium 
enhancement (LGE), LV asymmetry (>1.5-fold opposing segment) and systolic 
anterior motion of the mitral valve (SAM) were measured. Multivariate logistic 
regression was performed. Significance was defined as P<0.05. 
 
Results 
HHD and HCM cohorts were age-/gender-matched. HHD had significantly increased 
indexed LV mass (110±27g/m2 vs 91±31g/m2, P=0.016) but no difference in site or 
magnitude of maximal EDWT. Mid-wall LGE was significantly more prevalent in HCM. 
Elevated indexed LVM, mid-wall LGE and absence of SAM were significant 
multivariate predictors of HHD, but LV asymmetry was not.  
2 
 
Conclusions 
Increased Indexed LV mass, mid-wall LGE and absence of SAM are better CMR 
discriminators of HHD from HCM than EDWT ≥15mm.  
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Key points 
• Hypertrophic cardiomyopathy (HCM) is often diagnosed with end-diastolic 
wall thickness ≥15mm. 
• Hypertensive heart disease (HHD) can be difficult to distinguish from HCM. 
• Retrospective case-control study showed that location and magnitude of 
EDWT are poor discriminators. 
• Increased left ventricular mass, systolic anterior motion of the mitral valve 
and mid-wall fibrosis are independent predictor of HHD. 
• Cardiac magnetic resonance parameters facilitate a better discrimination 
between HHD and HCM. 
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Abbreviations 
ESC  - European Society of Cardiology 
HCM  - Hypertrophic cardiomyopathy 
LV  - Left ventricular 
EDWT  - End-diastolic wall thickness 
HHD  - Hypertensive heart disease 
CMR  - Cardiovascular magnetic resonance imaging 
LVH  - Left ventricular hypertrophy 
SAM  - Systolic anterior motion of the mitral valve / sub-valvular  
apparatus 
eGFR  - Estimated glomerular filtration rate 
SCD  -  Sudden cardiac death 
SSFP  - Steady state free precession 
BSA  - Body surface area 
RV  - Right ventricular 
EDV  - End-diastolic volume 
ESV  - End-systolic volume 
SV  -  Stroke volume 
EF  - Ejection fraction 
M/V  - Mass to volume ratio 
LGE  - Late gadolinium enhancement 
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INTRODUCTION 
The 2014 European Society of Cardiology (ESC) guidelines on hypertrophic 
cardiomyopathy (HCM) advocate that this condition should be considered when left 
ventricular (LV) end-diastolic wall thickness (EDWT) measures ≥15mm in ≥1 
myocardial segments, measured by any imaging technique[1]. Furthermore, 
according to the 2011 American College of Cardiology Foundation / American Heart 
Association guidelines, HCM is usually recognized by regional LV wall thickness 
≥15mm, with measurements of 13-14mm considered borderline[2]. Therefore, the 
pattern and degree of wall thickening are considered important in establishing a 
diagnosis of HCM. Concomitant abnormal loading conditions may confound the wall 
thickness cut-off. Concentric patterns of wall thickening are commonly thought to be 
associated with hypertension, the most common cause of increased afterload. 
However, asymmetric patterns of LV thickening have been described in hypertensive 
heart disease (HHD) with 2D echocardiography[3]. Cardiovascular magnetic 
resonance imaging (CMR) is currently non-invasive gold-standard for assessing LV 
mass, volume and EDWT[4][5]. The role of CMR in suspected HCM is recognized in 
International guidelines[1][6] and it is gaining an increasing role in certain 
hypertensive individuals[7]. Patients with suspected HCM and/or hypertension are 
increasingly being referred for CMR to attempt to distinguish between the two 
pathologies. To date, studies that have compared CMR findings in hypertension and 
HCM were either in subjects who fulfilled echocardiographic criteria for left 
ventricular hypertrophy (LVH)[8] or CMR criteria for LVH[9]. Wall thicknesses up to 
20mm have been described in previous CMR studies in hypertension[10], so being 
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able to distinguish HHD and HCM where EDWT is ≥15mm is important and, to date, 
not previous investigated. Consequently, the aims of this study were to compare 
age- and sex-mathced subjects with HHD with subject with HCM where EDWT 
≥15mm in both cohorts using a comprehensive multi-parametric CMR protocol. We 
sought to identify which CMR imaging findings can serve as discriminators between 
these two pathologies. We aimed to assess location and magnitude of hypertrophy, 
myocardial replacement fibrosis and ancillary imaging findings, such as systolic 
anterior motion of the mitral valve/sub-valvular apparatus (SAM) and aortoseptal 
angulation which have been described as markers of HCM[11].  
 
MATERIALS AND METHODS 
Hypertrophic cardiomyopathy study population 
This was a retrospective observational study from a prospectively maintained clinical 
CMR database of consecutive adult patients (>18 years old) referred for clinical CMR. 
Retrospective analysis of anonymized routine clinical data was confirmed to be in 
accordance with the NHS Health Research Authority guidelines for NHS research 
ethics approval. Subjects provided written consent for their CMR data to be used for 
post-hoc research. The diagnosis of HCM was based on the clinical information and 
CMR imaging findings of a non-dilated, hyper-dynamic hypertrophied LV in the 
absence of cardiac or systemic disease that could result in similar magnitude of 
hypertrophy, in a method previously described[9]. All patients with HCM had an 
expressed LV phenotype permitting an unequivocal diagnosis in the clinical context. 
Endomyocardial biopsy and/or genetic testing was not used to reach the 
diagnosis[12]. A total of 2481 CMR performed between 1st January and 31st 
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December 2014 were reviewed. Subjects without a diagnosis of HCM were excluded. 
Of those with a diagnosis of HCM and regional EDWT ≥15mm in ≥1 segment, those 
with apical only HCM, evidence of previous myocardial infarction, moderate-severe 
valvular heart disease and arterial hypertension (including elevated office blood 
pressure or on anti-hypertensive medications) were excluded. A severely decreased 
estimated glomerular filtration rate (eGFR) <30ml/min/1.73m2 was also an exclusion 
criterion, resulting in a final sample size of 464 myocardial segments from 29 
consecutive patients (Figure 1A). Medical records were reviewed for documented 
symptoms of heart failure, arrhythmia and family history of HCM, sudden cardiac 
death (SCD) or arrhythmia. 
 
Hypertensive heart disease study population 
150 patients with confirmed arterial hypertension were recruited from the Bristol 
Heart Institute tertiary hypertension clinic between February 2012 and April 2015. 
Subjects provided written consent. Baseline demographic and clinical characteristics 
were recorded. Hypertensive subjects with any concomitant myocardial pathology 
that may confound the hypertrophic response, e.g. moderate-severe valvular heart 
disease, acquired or inherited cardiomyopathy and suspected athlete’s heart, were 
excluded. An eGFR <30ml/min/1.73m2 was also an exclusion criterion. Hypertensive 
subjects with HHD with EDWT <15mm were also excluded. The final hypertensive 
sample size was 432 myocardial segments from 27 patients (Figure 1B). Medical 
records were reviewed for documented symptoms of heart failure, arrhythmia and 
family history of HCM, SCD or arrhythmia. 
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CMR protocol 
All CMRs were performed at 1.5T (Avanto, Siemens, Erlangen, Germany). Steady 
state free precession (SSFP) short axis whole LV cines (8mm slice thickness, no slice 
gap, temporal resolution 38.1ms, echo time 1.07ms, representative field of view in-
plane pixel size 1.5 x 0.8 mm) were used for the estimation of end-diastolic LV mass 
and LV volumes, which were then indexed to body surface area (BSA), as previously 
described[13]. Previously validated[14] threshold-detection software (CMR42, Circle 
Cardiovascular Imaging Inc., Calgary, Canada) was used to include papillary muscles 
and LV trabeculae to be included in LV mass estimation in accordance with the latest 
Society for Cardiovascular Magnetic Resonance imaging guidelines[15]. Papillary 
muscles and trabeculae were then included in the blood pool volume for assessment 
of end-diastolic volume (EDV), end-systolic volume (ESV), stroke volume (SV) and 
ejection fraction (EF), as described previously[13]. The LV mass/volume ratio (M/V), 
CMR equivalent of the echocardiogram-derived relative wall thickness 
measurement, was derived by dividing LV mass by EDV[16, 17].  
 
Average global longitudinal strain from 4-chamber and 2-chamber SSFP cines was 
measured with voxel-tracking post-processing software (TissueTracking, CVI42, Circle 
Cardiovascular Imaging Inc, Calgary). The presence of LV crypts, defined as previous 
as discrete approximately V- or U-shaped extensions of the blood signal, considered 
on cine viewing to penetrate >50% of the thickness of adjoining compact 
myocardium in diastole[18], was assessed visually. The presence of LV non-
compaction / hypertrabeculation was deemed present when the ratio of non-
compacted to compacted myocardium was >2.3 at end-diastole as previously 
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described[19]. All aforementioned CMR measurements and analyzes were 
performed by an experienced CMR reader blinded to the clinical details. 
 
Segmental end-diastolic wall thickness 
LV wall thickness was measured from the short-axis cines at end-diastole using pixel-
wise analysis (CMR42, Circle Cardiovascular Imaging Inc., Calgary, Canada). Briefly, 
endocardial and epicardial contours were defined, excluding right ventricular (RV) 
marginal septal trabeculations and LV papillary muscles and trabeculae. The 
automated software then mapped 100 cords, each perpendicular to the LV wall, per 
end-diastolic slice (Figure 2Aii and 2Bii). American Heart Association 16-segment 
model was generated automatically, using manually positioned anterior and inferior 
RV insertion points as reference markers. EDWT was defined as the mean thickness 
for each myocardial segment. Such measurements from short-axis cine CMR images 
have been demonstrated to result in good inter and intra-observer variability[20]. 
Asymmetrical segmental EDWT was defined as EDWT >1.5-fold the EDWT of the 
opposing segment, as previously described[21]. EDWT measurements were 
performed by an experienced CMR reader blinded to the clinical details and other 
CMR findings. 
 
Systolic anterior motion of the mitral valve / sub-valvular apparatus 
As previously described[11], systolic anterior motion of mitral valve (SAM) was 
defined as: i) partial when the mitral valve leaflets and/or chordae moved towards 
the ventricular septum but without direct contact during systole, as assessed on the 
3-chamber long-axis and short-axis cine stack, and ii) complete when there was 
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contact. The presence or absence of SAM was based on analysis of 2 independent 
CMR readers, with a consensus reading in cases of discrepancy. 
 
Aortoseptal angulation 
The aortoseptal angle was defined as the angle, on 3-chamber long-axis cine at end-
systole, between a line drawn along the right side of the interventricular septum 
(parallel to the proximal right ventricular endocardial border), and a line drawn 
through the long axis of the aortic root, where a value of 180o would be a straight 
line from septum to aorta and reducing values representing increased angulation, as 
previously described [11] (Figure 3). Aortoseptal angle measurements were 
performed by an experienced CMR reader, blinded to all other CMR and clinical data. 
 
Myocardial replacement fibrosis 
Myocardial replacement fibrosis was assessed by late gadolinium enhancement 
(LGE)[22]. An inversion-recovery fast gradient echo sequence performed, in two 
phase-encoding directions where required due to artifact, was performed 10-15 
minutes after intravenous administration of 0.1mmol/kg gadobutrol (Gadovist, Bayer 
Pharma AG, Germany). Tailored inversion times were used in each patient to achieve 
myocardial nulling. LGE presence and location were analyzed visually by 2 
independent experienced CMR readers, blinded to the clinical and hypertrophy data. 
The segmental distribution of LGE, including LGE at anterior/inferior basal/mid RV 
insertion points was recorded. Discrepancies were resolved by consensus. 
 
Statistical analysis 
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Statistical analysis was performed using SPSS Version 21 (Armonk, NY, USA: IBM 
Corp). Normally distributed continuous variables were expressed as mean ± standard 
deviation and compared using unpaired Student’s T test. Non-parametric data were 
compared with Mann-Whitney U test. Categorical variables were expressed as 
percentages and analysed using the Fisher’s exact test. Univariate and multivariate 
logistic regression analysis was performed to identify predictors of HHD compared to 
HCM. Significance was set at two-sided P<0.05. 
 
RESULTS 
Demographics 
Demographic data are displayed in Table 1. The HHD and HCM were matched in age 
(57±13years vs 62±10years, P=0.166) and sex (74% male vs 59% male, P=0.268). 
Subjects with HHD had significantly higher body mass index (33±5kg/m2 vs 
29±5kg/m2, P=0.003). Symptoms of arrhythmia and family history of SCD or 
arrhythmia were significantly more common in HCM compared to HHD. Within the 
hypertensive cohort, the mean office systolic blood pressure was 178±31mmHg and 
the mean office diastolic blood pressure was 98±15mmHg. Grading of blood 
pressure severity by 2013 ESH/ESC guidelines[7] was as follows: 7% controlled 
(SBP<140mmHg and DBP<90 mmHg), 15% Grade 1 (SBP 140-159 mmHg and/or DBP 
90-99mmHg), 11% Grade 2 (SBP 160-179mmHg and/or DBP 100-109mmHg), 48% 
Grade 3 (SBP ≥180mmHg and/or DBP ≥110mmHg) and 19% isolated systolic 
hypertension (SBP >140mmHg and DBP <90mmHg). 
 
Left ventricular mass 
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There was a significantly higher absolute LV mass in HHD compared to HCM 
(240±69g vs 175±64g, P<0.0001). There remained a significant difference when 
absolute LV mass was indexed to BSA (HHD: 110±27g/m2 vs HCM: 91±31g/m2, 
P=0.016). Due to the higher BMI in HHD, post-hoc analysis indexing LV mass to 
height1.7 was also performed. This allometric scaling method has recently been 
demonstrated to better account for obesity related increases in LV mass[23], and the 
significant difference persisted overall (HHD: 93±24g/m1.7 vs HCM: 74±30g/m1.7, 
P=0.008), and for female subjects (HHD: 76±16g/m1.7 vs HCM: 57±11g/m1.7, P=0.010) 
but only a non-significant trend for male subjects (HHD: 99±23g/m1.7vs HCM: 
84±33g/m1.7, P=0.108). 
 
Magnitude and location of segmental EDWT 
Representative examples of subjects with HHD and HCM are demonstrated in Figure 
2. The mean maximal EDWT thickness was not significantly different between HHD 
and HCM (16.9±1.5mm vs 17.5±2.9mm, P=0.988)(Table 2). In both cohorts, the basal 
anteroseptum (segment 2) was most likely to have EDWT ≥15mm (Figure 4A). There 
was no significant difference in the number of segments with EDWT ≥15mm per 
patient (HDD: 2.9±2.5 segments vs HCM: 2.6±2.1 segments, P=0.761). However, the 
basal and mid anterolateral and inferolateral, as well as all the apical segments, 
demonstrated significantly thicker EDWT in HHD compared to HCM (Table 3). 
Correspondingly, LV asymmetry was significantly more common in HCM than HHD, 
but nevertheless asymmetry still occurred in a large minority of HHD subjects (HCM 
asymmetry: 90% vs HHD asymmetry: 40%, P<0.0001).  
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Replacement fibrosis 
The location of mid-wall late gadolinium enhancement is demonstrated in Figure 4B. 
LGE was significantly more common in HCM than HHD in the basal anteroseptum 
(38% vs 4%, P=0.003), the mid inferoseptum (24% vs 0%, P=0.011) and all the RV 
insertion points (basal anterior RV insertion P<0.0001, basal inferior RV insertion 
P<0.0001, mid anterior RV insertion P=0.002, mid inferior RV insertion P=0.015). 
Similar significant differences were demonstrated in subgroup analysis of LGE in 
segments with EDWT ≥15mm (Figure 4C). 
 
Ancillary CMR findings 
Complete SAM was common in HCM and absent in HHD (41% vs 0%, 
P<0.0001)(Table 2). There were no significant differences either in the prevalence of 
partial SAM (HCM: 31% vs HHD: 11%, P=0.083) or in the mean aortoseptal angle 
(HCM: 113±10o vs 115±10o, P=0.481). LV crypts were more common in HCM than 
HHD (HCM: 13% vs HHD: 0%, P=0.05) but no cases of HHD or HCM met the criteria 
for LV non-compaction/hypertrabeculation. 
 
Predictors of HHD 
In univariate analysis, increasing BMI, LV mass indexed to BSA, absence of EDWT 
asymmetry, absence of SAM (partial or complete) and absence of mid-wall LGE were 
all significant predictors of HHD (Table 4). However, only increasing indexed LV mass, 
absence of SAM and absence of mid-wall LGE remained significant predictors in the 
multivariate logistic regression statistical model (Table 4). In area under the receiver 
operator curve analysis, indexed LV mass performed favorably at detecting HHD 
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(0.705 [0.567 – 0.843], P <0.05). An indexed LV mass threshold of 132g/m2 identified 
HHD over HCM with 93% specificity and 22% sensitivity (Figure 5). 
 
DISCUSSION 
This is the first study to investigate a comprehensive panel of multi-parametric CMR 
imaging findings as discriminators of hypertensive heart disease over hypertrophic 
cardiomyopathy when end-diastolic wall thickness, as measured by semi-automated 
pixel-wise CMR analysis, is ≥15mm in a total of 896 myocardial segments from age- 
and sex-matched cohorts. We show that the magnitude (both in terms of mean 
maximal EDWT and number of segments with EDWT ≥15mm) and location of wall 
thickening are not useful discriminators between HHD and HCM in this context. 
Furthermore, LV asymmetry, although significantly more common in HCM than HHD, 
was not a significant independent predictor of HCM in multivariate analysis. 
However, increasing LV mass indexed to BSA, the absence of SAM and the absence 
of myocardial replacement fibrosis were significant independent predictors of HHD 
in the multivariate logistic regression model. 
 
LV mass and location/magnitude of LV wall thickening 
There are conflicting results in the literature regarding the usefulness of LV mass at 
distinguishing HHD from HCM. Sipola et al. concluded that LV mass indexed to BSA 
was not useful at distinguishing 24 subjects with HCM from 94 subjects with mild-
moderate hypertension[24]. Puntmann et al. showed that LV mass indexed to BSA 
was significantly higher in 43 HCM subjects compared to 39 subjects with treated 
essential hypertension [9]. Rudolph et al. found no significant difference in LV mass 
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indexed to height in 36 HCM subjects compared to 26 hypertensive subjects, where 
all participants were drawn from a population with LVH by echocardiographic 
criteria[8]. Furthermore, 20% of subjects with HCM may have LV mass indexed to 
BSA within the normal range[25]. The heterogeneity in the literature likely relates to 
different study populations. In our clinically relevant cohort, where EDWT ≥15mm in 
both HHD and HCM cohorts, we show that LV mass indexed to both height1.7 and 
BSA is significantly higher in HHD and elevated indexed LV mass is a significant 
predictor of HHD over HCM in multivariate analysis. Our results provide further 
insight into a putative reason for this. We show that HHD is a concentric LV response 
to the increased afterload state, with significantly thicker segments in the mid lateral 
wall in particular compared to HCM. This is consistent with HCM being considered a 
more focal sacromeric disorder, rather than a global process. However, it is 
important to realize that LV asymmetry, whilst more common in HCM, was not a 
useful discriminator between HHD and HCM in multivariate analysis. Asymmetric 
HHD is well-recognized[26]. LV asymmetry, as defined at EDWT ≥15mm and >1.5 
times the opposing myocardial segment, occured in 40% of HHD in our cohort. This is 
markedly higher that previous echocardiographic studies, showing a prevalence of 
asymmetrical septal hypertrophy of 5%[3]. The reasons for this discrepancy, again, 
likely relate to different study populations; unselected subjects with hypertension in 
the echocardiographic study compared to subjects with hypertension and HHD with 
EDWT ≥15mm in our study. A additional explanation likely also relates to the better 
whole heart 3D coverage with contiguous short axis cines and better tissue contrast 
of CMR, facilitating the identification of endocardial contours, relative to 2D 
echocardiography[27]. However, the pathophysiology of asymmetric HHD is not fully 
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understood and possibly relate to the basal septum representing a site of increased 
wall stress in hypertension [28].  
 
Replacement fibrosis 
There are also conflicting results regarding the prevalence of myocardial 
replacement fibrosis between HCM and HHD. Puntmann et al. demonstrated a 
significantly higher global LGE score amongst HCM compared to HHD[9], whereas 
Rudolph et al. only demonstrated a non-significant trend towards higher prevalence 
of LGE in HCM (74%) than in hypertension (50%)[8]. The lack of significant difference 
in the latter study, likely relates to the high prevalence of LGE in their hypertensive 
subjects and such a higher prevalence of LGE in hypertension which has not been 
reproduced in subsequent studies[29]. For the first time, we show that mid-wall 
fibrosis is a significant discriminator between HHD and HCM in myocardial segments 
with EDWT ≥15mm. The markedly higher prevalence of LGE in HCM to HHD is 
consistent with the known pathophysiological differences between these conditions. 
HCM is characterized by myofibril disarray associated with interspersed 
microfibrosis[30], whereas, hypertensive LVH is a result of hypertrophy of existing 
cardiomyocytes, which occurs without structural disarray. However, the absence of 
LGE does not equate to the absence of myocardial fibrosis. The technique of 
acquiring LGE images with myocardial nulling requires a region of ‘normal’ 
myocardium for the nulling reference. This technique identifies focal replacement 
fibrosis but may fail to demonstrate global, diffuse fibrosis. T1 mapping techniques 
provide pixel-wise quantification of the myocardial intra and extracellular 
compartments and have already demonstrated increased diffuse myocardial 
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interstitial fibrosis in hypertensive LVH[29][31] and these techniques may also be 
useful to distinguish HCM from HHD[32].  
 
Limitations 
There are several limitations of our study. The absolute numbers of subjects in our 
study are low. However, the study is still the only study to date to compare HHD and 
HCM with EDWT ≥15mm, selected from a population of routine clinical CMR 
practice. However, analyzing each subject in a segment-wise manner significantly 
increased the number of data points in our study. However, the small sample size 
precluded further subgroup analysis to determine the length and severity of 
hypertension and the impact of anti-hypertensive medications on the degree of 
EDWT. The former may be particularly relevant as precursors of hypertensive heart 
phenotype have been demonstrated to be associated with increasing SBP in healthy 
adults[33]. 
 
An important consideration is the presence of hypertension in the HCM cohort and 
vice versa. In the HHD cohort, subjects with family history of HCM or sudden cardiac 
death were excluded. HCM subjects with documented elevated BP and controlled BP 
on anti-hypertensive medications were excluded.  
 
As quantification of peak velocity in the left ventricular outflow tract (LVOT) is not a 
routine component of our clinical multi-parametric CMR protocol for suspected 
HCM, this variable, as well as inducible LVOT obstruction, were not assessed. 
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In our study, we investigated predictors in subjects with expressed HHD and HCM 
phenotypes. The lack of endomyocardial biopsy and/or genetic testing is a limitation 
of our study. Further work is still required to refine discriminators in subjects with 
more mild disease states, supported by genetic profiling. In this regard, it would be 
interesting to incorporate CMR T1-mapping techniques in future studies to help 
distinguish these subjects by potentially demonstrating more intracellular 
(cardiomyocyte) expansion in hypertension and more extracellular expansion in 
HCM. 
 
Conclusions 
Distinguishing between hypertensive heart disease (HHD) and hypertrophic 
cardiomyopathy (HCM) can be difficult. International guidelines advocate using a 
wall thickness cut-off of 15mm for HCM. Our cardiovascular magnetic resonance 
imaging study highlights the most useful discriminating CMR imaging findings from 
routine clinical multi-parametric CMR. We demonstrate that an elevated indexed LV 
mass, the absence of mid-wall LGE and the absence of SAM are significant 
independent predictors of HHD over HCM in multivariate analysis in this context. The 
magnitude and location of the EDWT, as well as LV asymmetry, are not significant 
discriminators between HHD and HCM when EDWT is ≥15mm.  Our results suggest 
that the diagnosis of HCM on the basis of wall thickness alone should be made with 
caution in the context of concomitant hypertension. Tissue characterization with LGE 
is unique to CMR and supports its extended use in cases of suspected HCM, 
particularly where there is concomitant hypertension. 
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Table 1: Demographic data for hypertensive heart disease and hypertrophic 
cardiomyopathy cohorts 
 
Table 2: CMR data for hypertensive heart disease and hypertrophic cardiomyopathy 
cohorts 
 
Table 3: Mean maximal end-diastolic wall thickness in each myocardial segment for 
hypertensive heart disease and hypertrophic cardiomyopathy cohorts 
 
Table 4: Univariate and multivariate logistic regression analysis of predictors of 
hypertensive heart disease compared to hypertrophic cardiomyopathy 
 
Figure 1. Flow-charts demonstrating study exclusion criteria. A) Hypertrophic 
cardiomyopathy sample size (n=29). B) Hypertensive heart disease sample size 
(n=27). *Image artifact from implantable loop recorder device precluding volumetric 
assessment from LV short axis stack. CMR = cardiac magnetic resonance, HCM = 
hypertrophic cardiomyopathy, HTN = hypertension, EDWT = end-diastolic wall 
thickness, MI = myocardial infarction, HCM = hypertrophic cardiomyopathy, LVNC = 
left ventricular non-compaction cardiomyopathy, DCM = idiopathic dilated 
cardiomyopathy, Mod AR = moderate aortic regurgitation, AVR = aortic valve 
replacement. 
 
Figure 2. Examples of patients with end-diastolic wall thickness ≥15mm. A) 
Hypertensive heart disease: i-ii) Steady state free precession (SSFP) mid short-axis 
cine at end-diastole with maximal asymmetric wall thickness of 15.9mm, iii) 
25 
Inversion recovery (IR-LGE) mid short-axis image showing subtle replacement fibrosis 
at the anterior right ventricular insertion point only (white arrow), iv) SSFP 3-
chamber cine at end-systole demonstrating no systolic anterior motion of the mitral 
valve (SAM). B) Hypertrophic cardiomyopathy: i-ii) SSFP mid short-axis cine at end-
diastole with maximal asymmetric wall thickness of 16.3mm, iii) IR-LGE mid short-
axis image showing extensive myocardial replacement fibrosis (white arrows), iv) 
SSFP 3-chamber cine at end-systole demonstrating SAM and associated mitral 
regurgitation (white arrows). 
 
Figure 3. Representative example of measuring the aortoseptal angle. 
 
Figure 4. Segmental distribution of end-diastolic wall thickness (EDWT) ≥15mm and 
prevalence of late gadolinium enhancement (LGE). A) American Heart Association 
(AHA) 16-segment plot demonstrating percentage of segments with EDWT ≥15mm in 
i) hypertensive heart disease (HHD) and ii) hypertrophic cardiomyopathy (HCM). B) 
AHA 16-segment plot demonstrating prevalence of segmental mid-wall and right 
ventricular insertion point LGE in i) HHD and ii) HCM. C) AHA 16-segment plot 
demonstrating prevalence of segmental mid-wall LGE in segments with EDWT 
≥15mm in i) HHD and ii) HCM. 
 
Figure 5. Receiver operating curve for indexed LV mass at detecting hypertensive 
heart disease compared to hypertrophic cardiomyopathy.  
